EXEL vs. RGC: A Head-to-Head Stock Comparison

Updated on August 19, 2025

Here’s a clear look at EXEL and RGC, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.

Company Profile

Symbol	EXEL	RGC
Company Name	Exelixis, Inc.	Regencell Bioscience Holdings Limited
Country	United States	Hong Kong
GICS Sector	Health Care	Health Care
GICS Industry	Biotechnology	Pharmaceuticals
Market Capitalization	10.36 billion USD	6.64 billion USD
Exchange	NasdaqGS	NasdaqCM
Listing Date	April 17, 2000	July 16, 2021
Security Type	Common Stock	Common Stock

Historical Performance

This chart compares the performance of EXEL and RGC by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.

EXEL vs. RGC: Growth of a $10,000 investment over the past one year.

Historical Performance at a Glance

Symbol	EXEL	RGC
5-Day Price Return	2.94%	6.67%
13-Week Price Return	4.08%	39.56%
26-Week Price Return	14.32%	13,340.00%
52-Week Price Return	42.93%	3,740.00%
Month-to-Date Return	6.27%	1.82%
Year-to-Date Return	15.59%	10,238.46%
10-Day Avg. Volume	3.51M	0.31M
3-Month Avg. Volume	3.38M	2.51M
3-Month Volatility	62.34%	664.33%
Beta	0.36	2.35

Profitability

Return on Equity (TTM)

EXEL

27.74%

Biotechnology Industry

Max: 77.14%
Q3: 10.76%
Median: -20.08%
Q1: -42.71%
Min: -119.20%

In the upper quartile for the Biotechnology industry, EXEL’s Return on Equity of 27.74% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.

RGC

-54.75%

Pharmaceuticals Industry

Max: 38.59%
Q3: 19.84%
Median: 11.90%
Q1: 5.63%
Min: -9.96%

RGC has a negative Return on Equity of -54.75%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.

EXEL vs. RGC: A comparison of their Return on Equity (TTM) against their respective Biotechnology and Pharmaceuticals industry benchmarks.

Net Profit Margin (TTM)

EXEL

27.01%

Biotechnology Industry

Max: 59.44%
Q3: 16.21%
Median: -11.49%
Q1: -167.42%
Min: -409.07%

A Net Profit Margin of 27.01% places EXEL in the upper quartile for the Biotechnology industry, signifying strong profitability and more effective cost management than most of its peers.

RGC

Pharmaceuticals Industry

Max: 34.51%
Q3: 17.73%
Median: 12.12%
Q1: 5.99%
Min: -7.73%

Net Profit Margin data for RGC is currently unavailable.

EXEL vs. RGC: A comparison of their Net Profit Margin (TTM) against their respective Biotechnology and Pharmaceuticals industry benchmarks.

Operating Profit Margin (TTM)

EXEL

31.38%

Biotechnology Industry

Max: 60.62%
Q3: 20.76%
Median: -12.41%
Q1: -181.14%
Min: -482.02%

An Operating Profit Margin of 31.38% places EXEL in the upper quartile for the Biotechnology industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.

RGC

Pharmaceuticals Industry

Max: 41.53%
Q3: 23.00%
Median: 16.24%
Q1: 9.24%
Min: -6.94%

Operating Profit Margin data for RGC is currently unavailable.

EXEL vs. RGC: A comparison of their Operating Profit Margin (TTM) against their respective Biotechnology and Pharmaceuticals industry benchmarks.

Profitability at a Glance

Symbol	EXEL	RGC
Return on Equity (TTM)	27.74%	-54.75%
Return on Assets (TTM)	21.09%	-51.38%
Net Profit Margin (TTM)	27.01%	--
Operating Profit Margin (TTM)	31.38%	--
Gross Profit Margin (TTM)	96.59%	--

Financial Strength

Current Ratio (MRQ)

EXEL

3.51

Biotechnology Industry

Max: 19.31
Q3: 9.38
Median: 4.54
Q1: 2.45
Min: 0.76

EXEL’s Current Ratio of 3.51 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.

RGC

42.68

Pharmaceuticals Industry

Max: 4.49
Q3: 2.77
Median: 1.74
Q1: 1.26
Min: 0.11

RGC’s Current Ratio of 42.68 is exceptionally high, placing it well outside the typical range for the Pharmaceuticals industry. This indicates a very strong liquidity position, though such a high ratio may also suggest that the company is not using its assets efficiently to generate profits.

EXEL vs. RGC: A comparison of their Current Ratio (MRQ) against their respective Biotechnology and Pharmaceuticals industry benchmarks.

Debt-to-Equity Ratio (MRQ)

EXEL

0.00

Biotechnology Industry

Max: 1.35
Q3: 0.64
Median: 0.09
Q1: 0.00
Min: 0.00

EXEL’s Debt-to-Equity Ratio of 0.00 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.

RGC

0.00

Pharmaceuticals Industry

Max: 2.44
Q3: 1.07
Median: 0.42
Q1: 0.11
Min: 0.00

Falling into the lower quartile for the Pharmaceuticals industry, RGC’s Debt-to-Equity Ratio of 0.00 points to a conservative financing strategy. This results in lower financial risk but potentially limits strategic investments compared to more leveraged competitors.

EXEL vs. RGC: A comparison of their Debt-to-Equity Ratio (MRQ) against their respective Biotechnology and Pharmaceuticals industry benchmarks.

Interest Coverage Ratio (TTM)

EXEL

42.74

Biotechnology Industry

Max: 72.37
Q3: 1.91
Median: -7.81
Q1: -63.90
Min: -153.80

EXEL’s Interest Coverage Ratio of 42.74 is in the upper quartile for the Biotechnology industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.

RGC

Pharmaceuticals Industry

Max: 103.95
Q3: 44.18
Median: 9.83
Q1: 2.82
Min: -42.71

Interest Coverage Ratio data for RGC is currently unavailable.

EXEL vs. RGC: A comparison of their Interest Coverage Ratio (TTM) against their respective Biotechnology and Pharmaceuticals industry benchmarks.

Financial Strength at a Glance

Symbol	EXEL	RGC
Current Ratio (MRQ)	3.51	42.68
Quick Ratio (MRQ)	3.22	41.89
Debt-to-Equity Ratio (MRQ)	0.00	0.00
Interest Coverage Ratio (TTM)	42.74	--

Growth

Revenue Growth

EXEL vs. RGC: A side-by-side comparison of their Revenue Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

EPS Growth

EXEL vs. RGC: A side-by-side comparison of their EPS Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

Dividend

Dividend Yield (TTM)

EXEL

0.00%

Biotechnology Industry

Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

EXEL currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.

RGC

0.00%

Pharmaceuticals Industry

Max: 6.98%
Q3: 3.32%
Median: 2.13%
Q1: 0.14%
Min: 0.00%

RGC currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.

EXEL vs. RGC: A comparison of their Dividend Yield (TTM) against their respective Biotechnology and Pharmaceuticals industry benchmarks.

Dividend Payout Ratio (TTM)

EXEL

0.00%

Biotechnology Industry

Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

EXEL has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.

RGC

0.00%

Pharmaceuticals Industry

Max: 165.20%
Q3: 90.59%
Median: 49.13%
Q1: 28.91%
Min: 0.00%

RGC has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.

EXEL vs. RGC: A comparison of their Dividend Payout Ratio (TTM) against their respective Biotechnology and Pharmaceuticals industry benchmarks.

Dividend at a Glance

Symbol	EXEL	RGC
Dividend Yield (TTM)	0.00%	0.00%
Dividend Payout Ratio (TTM)	0.00%	0.00%

Valuation

Price-to-Earnings Ratio (TTM)

EXEL

17.18

Biotechnology Industry

Max: 60.14
Q3: 38.17
Median: 29.01
Q1: 15.12
Min: 0.00

EXEL’s P/E Ratio of 17.18 is within the middle range for the Biotechnology industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.

RGC

Pharmaceuticals Industry

Max: 42.51
Q3: 26.88
Median: 19.11
Q1: 15.12
Min: 0.00

P/E Ratio data for RGC is currently unavailable.

EXEL vs. RGC: A comparison of their Price-to-Earnings Ratio (TTM) against their respective Biotechnology and Pharmaceuticals industry benchmarks.

Price-to-Sales Ratio (TTM)

EXEL

4.64

Biotechnology Industry

Max: 76.98
Q3: 36.53
Median: 9.49
Q1: 4.49
Min: 0.00

EXEL’s P/S Ratio of 4.64 aligns with the market consensus for the Biotechnology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.

RGC

Pharmaceuticals Industry

Max: 7.55
Q3: 4.54
Median: 2.11
Q1: 1.52
Min: 0.00

P/S Ratio data for RGC is currently unavailable.

EXEL vs. RGC: A comparison of their Price-to-Sales Ratio (TTM) against their respective Biotechnology and Pharmaceuticals industry benchmarks.

Price-to-Book Ratio (MRQ)

EXEL

6.19

Biotechnology Industry

Max: 20.53
Q3: 9.76
Median: 4.77
Q1: 2.49
Min: 0.59

EXEL’s P/B Ratio of 6.19 is within the conventional range for the Biotechnology industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.

RGC

9.57

Pharmaceuticals Industry

Max: 9.78
Q3: 4.96
Median: 2.23
Q1: 1.46
Min: 0.60

RGC’s P/B Ratio of 9.57 is in the upper tier for the Pharmaceuticals industry. This indicates that investors are paying a premium relative to the company’s net assets, a valuation that hinges on its ability to generate superior profits.

EXEL vs. RGC: A comparison of their Price-to-Book Ratio (MRQ) against their respective Biotechnology and Pharmaceuticals industry benchmarks.

Valuation at a Glance

Symbol	EXEL	RGC
Price-to-Earnings Ratio (TTM)	17.18	--
Price-to-Sales Ratio (TTM)	4.64	--
Price-to-Book Ratio (MRQ)	6.19	9.57
Price-to-Free Cash Flow Ratio (TTM)	13.72	--